

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS F O Box 1450 Alexandria, Virginia 23313-1450 www.uspilo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/977,823	10/15/2001	James J. Rudnick	S63.2N-14438-US04	4655	
	7590 12/15/201 TT & STEINKRAUS.	EXAM	EXAMINER		
SUITE 400, 6640 SHADY OAK ROAD EDEN PRAIRIE, MN 55344			SCHILLINGER, ANN M		
			ART UNIT	PAPER NUMBER	
			3774		
			MAIL DATE	DELIVERY MODE	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)		
09/977,823		RUDNICK ET AL.		
	Examiner	Art Unit		
	ANN SCHILLINGER	3774		

_c.c.c me i mily ci am i ippear _me	Examine	ALCOING					
	ANN SCHILLINGER	3774					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED 24 November 2010 FAILS TO PLACE THIS	S APPLICATION IN CONDITION F	OR ALLOWANCE.					
 X he reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Applor for Continued Examination (RCE) in compliance with 37 (periods: 	The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 4.1.31 or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:						
a) The period for reply expiresmonths from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is late no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.							
Examiner Note: If box 1 is checked, check either box (a) or MONTHS OF THE FINAL REJECTION. See MPEP 706.07(
Extensions of time may be obtained under 37 CFR 1.198(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b) NOTICE CF APPEAL.	tension and the corresponding amount shortened statutory period for reply origithan three months after the mailing dat .	of the fee. The appropris nally set in the final Offic e of the final rejection, e	ate extension fee e action; or (2) as ven if timely filed,				
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte Notice of Appeal has been filed, any reply must be filed w 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	of the date of appeal. Since				
<u>AMENDMENTS</u>							
 The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for 							
appeal; and/or (d) ☐ They present additional claims without canceling a							
NOTE: (See 37 CFR 1.116 and 41.33(a)).							
 The amendments are not in compliance with 37 CFR 1.1. 		mpliant Amendment (PTOL-324).				
 Applicant's reply has overcome the following rejection(s) 							
 Newly proposed or amended claim(s) would be al non-allowable claim(s). 	·		_				
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is profile status of the claim(s) is (or will be) as follows:		l be entered and an e	xplanation of				
Claim(s) allowed:							
Claim(s) objected to:Claim(s) rejected: 19,21-24,26-35 and 38-42. Claim(s) withdrawn from consideration: .							
AFFIDAVIT OR OTHER EVIDENCE							
The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).	It before or on the date of filing a No d sufficient reasons why the affidavi	otice of Appeal will <u>not</u> it or other evidence is	be entered necessary and				
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessar. 	vercome <u>all</u> rejections under appea y and was not earlier presented. Se	al and/or appellant fail: se 37 CFR 41.33(d)(1	s to provide a).				
10. The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.				
 The request for reconsideration has been considered bu <u>See Continuation Sheet.</u> 	t does NOT place the application in	condition for allowan	ce because:				
12. Note the attached Information <i>Disclosure Statement</i> (s). 13. Other:	(PTO/SB/08) Paper No(s)						
/DAVID ISABELLA/ Supervisory Patent Examiner, Art Unit 3774	/A. S./ Examiner, Art Unit 3774						

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Continuation of 11. does NOT place the application in condition for allowance because: Examiner thanks the Applicant for pointing out Figures 2 and 5 from the application. However, the specification and the drawings do not dearly and explicitly show the stent's windings being in contact with one another, therefore, the 35 U.S.C. 112 rejection against the claims is maintained. The Timmermans reference is constructed from nitinol and made to be subjected to a variety of degrees of compression. The stent disclosed by Timmermans would then be capable of being compressed to a point where the windings contact one another.